 Approximately two-thirds of patients diagnosed with non-small cell lung cancer NSCLC are 65 years or older, and nearly 50 are 70 years or older. And greater than 90 of elderly patients experience a grade 34 toxicity when treated with a platinum-based doublet..Moreover,a group of patients with the performance status 2 is intolerant intravenous chemotherapy. Availability of an effective,less toxic therapy might help extend potentially beneficial treatment to a greater proportion of elderly or patients whose performance status 2. 